Drugs / 11C-Choline
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01377220 | Jun 2011 → Jun 2013 | hepatocellular carcinoma | French Alternative Energies and Atomic Energy Commission | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02260817 | Oct 2014 → Jun 2016 | metastatic prostate carcinoma | Global Isotopes, LLC d/b/a Zevacor Molecular | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04693169 | Jan 2021 → Jun 2024 | prostate cancer | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| — | NCT04560725 | Oct 2020 → Dec 2024 overdue | prostate cancer | Peking University Cancer Hospital & Institute | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02531672 | — | prostate carcinoma | Memorial Sloan Kettering Cancer Center | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11C-choline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02260817 ↗ |
| Modality | Diagnostic / imaging agent | “11C-choline PET-CT performance for HCC diagnosis” NCT01377220 ↗ |
| Route | Intravenous | “11C-Choline : 6MBq/kg on direct intravenous on one minute.” NCT01377220 ↗ |